Harmony Biosciences price to sales ratio HRMY

Market value divided by revenue over the last twelve months, since 2021.

Today, Oct 23, 2026: 2.2×
5-year median: 3.1×
Against its 5-year history: 9th; percentile: 0 is its lowest day, 100 its highest
5-year range: 1.8× to 10.2×
Peer median: 2.0×

Harmony Biosciences' price to sales ratio is 2.2× as of Oct 23, 2026.

That is below its 5-year median of 3.1×, lower than on 91% of days in the last 5 years.

Over that time it ranged from 1.8× in Mar 2026 to 10.2× in Nov 2021.

The median for 10 large drugmakers of a similar size is 2.0×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.2×	1.8×	2.7×
2025	2.7×	1.9×	3.3×
2024	2.9×	2.7×	3.7×
2023	3.5×	2.3×	7.9×
2022	8.2×	6.3×	9.9×
2021	9.2×	7.7×	10.2×

Against its peers

Companies in Drug Manufacturers - General nearest Harmony Biosciences' size, closest first, today.

Company	Price to sales ratio
HRMYHarmony Biosciences	2.2×
PBHPrestige Consumer Healthcare	2.0×
ANIPANI Pharmaceuticals	1.7×
NRIXNurix Therapeutics	3.9×
PAHCPhibro Animal Health	1.0×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	1.9×
OGNOrganon	0.6×
OMEROmeros	n/m
LQDALiquidia	8.5×
ARQTArcutis Biotherapeutics	8.5×
Peer median	2.0×

Where Harmony Biosciences ranks

#46of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Harmony Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.